Preparation of benznidazole pellets for immediate drug delivery using the extrusion spheronization technique

References

• Chatelain E. Chagas disease drug discovery: toward a new era. J Biomol Screen 2015;20:22–35.
   PubMed Web of Science ®Google Scholar
• World Health Organization Fact Sheet n 340; 2015.
   Google Scholar
• Gascon J, Bern C, Pinazo MJ. Chagas disease in Spain, the United States and other non-endemic countries. Acta Trop 2010;115:22–7.
   PubMed Web of Science ®Google Scholar
• Bern C, Montgomery SP. An estimate of the burden of Chagas disease in the United States. Clin Infect Dis 2009;49:52–4.
   PubMed Web of Science ®Google Scholar
• Maximiniano FP, Novack KM, Bahia MT, et al. Polymorphic screen and drug-excipient compatibility studies of the antichagasic benznidazole. J Therm Anal Calorim 2011;106:819–24.
   Web of Science ®Google Scholar
• Morilla MJ, Benavidez PE, Lopez MO, et al. Liposomal benznidazole: a high-performance liquid chromatographic determination for biodistribution studies. J Chromatogr Sci 2003;41:405–9.
   PubMed Web of Science ®Google Scholar
• Mosqueira VCF, Oliveira LT, Castanheira RG. Micro- and nanostructured pharmaceutical and veterinary compositions, containing benznidazole and derivatives thereof, which form micro- and nanostructures in the gastrointestinal tract, and biological uses thereof. PCT Int. Appl. WO 2015039199; 2015.
   Google Scholar
• Leonardi D, Salomon CJ, Lamas MC, et al. Development of novel formulations for Chagas' disease: optimization of benznidazole chitosan microparticles based on artificial neural networks. Int J Pharm 2009;367:40–7.
   Web of Science ®Google Scholar
• Maximiano FP, Paula LM, Figueiredo VP, et al. Benznidazole microcrystal preparation by solvent change precipitation and in vivo evaluation in the treatment of Chagas disease. Eur J Pharm Biopharm 2011;78:377–84.
   PubMed Web of Science ®Google Scholar
• Maximiano FP, Costa GHY, Barreto LCL, et al. Development of effervescent tablets containing benznidazole complexed with cyclodextrin. J Pharm Pharmacol 2011;63:786–93.
   PubMed Web of Science ®Google Scholar
• Lyra MAM, Soares-Sobrinho JL, Figueiredo RCBQ, et al. Study of benznidazole-cyclodextrin inclusion complexes, cytotoxicity and trypanocidal activity. J Incl Phenom Macrocycl Chem 2012;73:397–404.
   Web of Science ®Google Scholar
• Soares-Sobrinho JL, Santos FLA, Lyra MAM, et al. Benznidazole drug delivery by binary and multicomponent inclusion complexes using cyclodextrins and polymers. Carbohydr Polym 2012;89:323–30.
   PubMed Web of Science ®Google Scholar
• Leonardi D, Salomon CJ. Unexpected performance of physical mixtures over solid dispersions on the dissolution behavior of benznidazole from tablets. J Pharm Sci 2013;102:1016–23.
   PubMed Web of Science ®Google Scholar
• Palmeiro-Roldan R, Fonseca-Berzal C, Gomez-Barrio A, et al. Development of novel benznidazole formulations: physicochemical characterization and in vivo evaluation on parasitemia reduction in Chagas disease. Int J Pharm 2014;472:110–7.
   PubMed Web of Science ®Google Scholar
• Fonseca-Berzal C, Palmeiro-Roldan R, Escario JA, et al. Novel solid dispersions of benznidazole: preparation, dissolution profile and biological evaluation as alternative antichagasic drug delivery system. Exp Parasitol 2015;149:84–91.
   PubMed Web of Science ®Google Scholar
• Altcheh J, Moscatelli G, Mastrantonio G, et al. Population pharmacokinetic study of benznidazole in pediatric Chagas disease suggests efficacy despite lower plasma concentrations than in adults. PLoS Negl Trop Dis 2014;8:e2907.
   PubMed Web of Science ®Google Scholar
• Bahia MT, Diniz LF, Mosqueira VCF. Therapeutical approaches under investigation for treatment of Chagas disease. Expert Opin Investig Drugs 2014;23:1225–37.
   PubMed Web of Science ®Google Scholar
• Planer JD, Hulverson MA, Arif JA, et al. Synergy testing of FDA-approved drugs identifies potent drug combinations against Trypanosoma cruzi. PLoS Negl Trop Dis 2014;8:e2977–1.
   PubMed Web of Science ®Google Scholar
• Strauss M, Presti LP, Bazan PC, et al. Rivarolastrauss, clomipramine and benznidazole association for the treatment of acute experimental Trypanosoma cruzi infection. Parasitol Int 2013;62:293–9.
   PubMed Web of Science ®Google Scholar
• Martins TAF, Diniz LF, Mazzeti AL, et al. Benznidazole/itraconazole combination treatment enhances anti-trypanosoma cruzi activity in experimental Chagas disease. PLoS One 2015;15:e0128707.
   Google Scholar
• Alves-Silva I, Sá-Barreto LCL, Lima EM, et al. Preformulation studies of itraconazole associated with benznidazole and pharmaceutical excipients. Thermochim Acta 2014;575:29–33.
   Web of Science ®Google Scholar
• Abdul S, Chandewar AV, Jaiswal SB. A flexible technology for modified-release drugs: multiple-unit pellet system (MUPS). J Control Release 2010;147:2–16.
   PubMed Web of Science ®Google Scholar
• Dukic-Ott A, Thommes M, Remon JP, et al. Production of pellets via extrusion–spheronisation without the incorporation of microcrystalline cellulose: a critical review. Eur J Pharm Biopharm 2009;71:38–46.
   PubMed Web of Science ®Google Scholar
• Gomez-Amoza JL, Matinez-Pacheco R. Influence of microstructure on drug release from extrusion–spheronization pellets. J Drug Deliv Sci Technol 2010;20:319–25.
   Web of Science ®Google Scholar
• Souto C, Rodríguez A, Parajes S, et al. Comparative study of the utility of two superdisintegrants in microcrystalline cellulose pellets prepared by extrusion–spheronisation. Eur J Pharm Biopharm 2005;61:94–9.
   PubMed Web of Science ®Google Scholar
• Kranz H, Juergens K, Pinier M, et al. Drug release from MCC- and carrageenan-based pellets: experiment and theory. Eur J Pharm Biopharm 2009;73:302–9.
   PubMed Web of Science ®Google Scholar
• Goyanes A, Souto C, Martínez-Pacheco R. A comparison of chitosan-silica and sodium starch glycolate as disintegrants for spheronized extruded microcrystalline cellulose pellets. Drug Dev Ind Pharm 2011;37:825–31.
   PubMed Web of Science ®Google Scholar
• Chamsai B, Sriamornsak P. Novel disintegrating microcrystalline cellulose pellets with improved drug dissolution performance. Powder Technol 2013;233:278–85.
   Web of Science ®Google Scholar
• Goyanes A, Souto C, Martinez-Pacheco R. Chitosan-kaolin coprecipitate as disintegrant in microcrystalline cellulose-based pellets elaborated by extrusion–spheronization. Pharm Dev Technol 2013;18:137–45.
   PubMed Web of Science ®Google Scholar
• Goyanes A, Martinez-Pacheco R. New co-processed MCC-based excipient for fast release of low solubility drugs from pellets prepared by extrusion–spheronization. Drug Dev Ind Pharm 2015;41:362–8.
   PubMed Web of Science ®Google Scholar
• Nirmal M. Controlled release pharmaceutical compositions. United States Patent US 20140044787 A1; 2014 Feb 13.
   Google Scholar
• Goyanes A, Souto C, Martínez-Pacheco R. Control of drug release by incorporation of sorbitol or mannitol in microcrystalline-cellulose-base pellets prepared by extrusion–spheronization. Pharm Dev Technol 2010;15:636–5.
   PubMed Web of Science ®Google Scholar
• Sahah RB, Tawakkul MA, Khan MA. Comparative evaluation of flow for pharmaceutical powders and granules. AAPS PharmaSciTech 2008;9:250–8.
   PubMed Web of Science ®Google Scholar
• Verva C. Enhancement of in-vitro drug-release by using polyethylene-glycol-400 and PEG-40 hydrogenated castor-oil in pellets made by extrusion–spheronisation. Int J Pharm 1994;108:207–12.
   Web of Science ®Google Scholar
• Rowe CR, Sheskey PJ, Quinn ME. Handbook of pharmaceutical excipients. Vol. 6. London: Pharmaceutical Press; 2009.
   Google Scholar
• Maximiano FP, Costa GHY, Souza J, Cunha-Filho MSS. Physicochemical characterization of antichagasic benznidazole. Quim Nov 2010;33:1714–9.
   Web of Science ®Google Scholar
• Rojas J, Guisao S, Ruge V. Functional assessment of four types of disintegrant and their effect on the spironolactone release properties. AAPS PharmSciTech 2012;13:1054–62.
   PubMed Web of Science ®Google Scholar